6/5
08:04 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
6/3
08:08 am
aqst
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities [Yahoo! Finance]
Low
Report
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities [Yahoo! Finance]
6/3
08:00 am
aqst
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
Low
Report
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
5/28
08:24 am
aqst
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference [Yahoo! Finance]
Low
Report
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference [Yahoo! Finance]
5/28
08:00 am
aqst
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
Low
Report
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
5/16
03:06 pm
aqst
Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5% [Yahoo! Finance]
Low
Report
Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5% [Yahoo! Finance]
5/14
07:44 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
5/10
07:30 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $8.00 price target on the stock.
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $8.00 price target on the stock.
5/9
05:07 pm
aqst
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
08:23 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]
5/9
08:17 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
5/9
08:00 am
aqst
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
Medium
Report
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
5/7
08:10 pm
aqst
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics [Yahoo! Finance]
Low
Report
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics [Yahoo! Finance]
5/7
07:13 pm
aqst
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
5/7
04:27 pm
aqst
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/7
04:19 pm
aqst
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4/30
08:12 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
4/29
07:13 am
aqst
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film [Yahoo! Finance]
4/29
07:00 am
aqst
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Medium
Report
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
4/25
08:00 am
aqst
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
Low
Report
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
4/12
04:06 pm
aqst
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology [Yahoo! Finance]
Low
Report
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology [Yahoo! Finance]
4/12
04:01 pm
aqst
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
Low
Report
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
4/11
07:28 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $10.00 price target on the stock.
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $10.00 price target on the stock.
4/9
01:29 am
aqst
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 [Seeking Alpha]
Low
Report
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 [Seeking Alpha]
4/5
08:03 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.